Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca’s Forxiga approved in Japan for the treatment of CKD

Approval was based on positive data from the phase 3 trial for chronic kidney disease

AstraZeneca

Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for the treatment of chronic kidney disease (CKD) in adults with and without type 2 diabetes.

Forxiga is the first ever approved medicine for the treatment of the disease in Japan.

The decision follows positive results from the DAPA-CKD phase 3 trial, which demonstrated that Forxiga reduced the relative risk of worsening of renal function, onset of end-stage kidney disease (ESKD), or risk of cardiovascular (CV) or renal death by 39%.

Naoki Kashihara, the national coordinator of the trial in Japan and president of the Japanese Society of Nephrology, said: “DAPA-CKD is the landmark trial that demonstrated unprecedented risk reduction for chronic kidney disease patients with and without type 2 diabetes.”

Mene Pangalos, executive vice president, BioPharmaceuticals R&D, said: “This approval is an important step towards realising our ambition of improving outcomes for patients with chronic kidney disease. While new medicines like Forxiga advance the standard of care, we are also committed to the prevention and early detection of this often debilitating and life-threatening disease.”

Ono Pharmaceutical has distribution rights for Forxiga in Japan and will co-promote the drug for the treatment of CKD along with AstraZeneca.

Forxiga was approved as ‘Farxiga’ for the treatment of CKD in adults with and without type 2 diabetes in the US in April, after demonstrating results from a phase 3 study of the drug at the European Society of Cardiology (ESC) virtual congress in January. It was approved in the EU in August and according to AstraZeneca is currently under review in several other countries around the world.

Article by
Bryony Andrews

27th August 2021

From: Regulatory

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
Omnichannel strategies to revolutionize the healthcare professional experience
Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...
The digital-first launch: the key to connected stakeholder experiences?
During the COVID-19 pandemic, a new digital-first launch model emerged as a gamechanger for driving better customer experiences. Here, Senior Consultant Srividya Sekar; Senior Associate Consultant, Erin Johnstone; and Associate...